 |
|
Quality of Care in the Diagnosis of Melanoma and Related Melanocytic Lesions
Michael Piepkorn, MD, PhD;
Peter B. Odland, MD
Arch Dermatol. 1997;133(11):1393-1396.
Abstract
Few issues in dermatologic practice evoke as much debate and controversy as do the diagnosis and management of melanocytic lesions. Not least among the reasons for this is the potential for untoward outcomes. On one hand, this may well constitute death from the disease for the patient. The magnitude of such tragedies is often compounded by the tendency of melanoma to afflict persons during the prime of their lives. On the other hand, it requires little further elaboration that dermatologic practitioners may be exposed to significant liability when they are treating patients with this disease.1 Regrettably, the degree of debate and the magnitude of the attendant rhetoric seem inversely proportional to the substance and quality of the database, reflecting an all-too-common theme in medical practice. Now that quality of care has suddenly become a watchword and a major focus of concern in health care delivery systems, replacing such moribund issues as access to care, we as providers are coming under increasing pressures to demonstrate that our rendered services meet certain nebulous performance standards and other measures of quality that are under development.2-8
Author Affiliations
From the Departments of Medicine (Drs Piepkorn and Odland) and Pathology (Dr Piepkorn), University of Washington School of Medicine, Seattle.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Genomic Approaches to Skin Cancer Diagnosis
Bastian et al.
Arch Dermatol 2001;137:1507-1511.
FULL TEXT
Is Routine Screening for Melanoma a Benign Practice?
Edman and Klaus
JAMA 2000;284:883-886.
FULL TEXT
Quality of Care in Dermatology: The State of (Measuring) the Art
Chren
Arch Dermatol 1997;133:1349-1351.
ABSTRACT
|
